Ellis Bio

Executive Summary

Ellis Bio is a San Diego-based biotechnology company founded in 2021, specializing in epigenomic tools for DNA methylation analysis. The company's flagship product line, SuperMethyl™, comprises kits designed to deliver high accuracy, low-input requirements, and fast turnaround times, aiming to democratize access to advanced methylation analysis for researchers and clinicians globally. As a private, early-stage company, Ellis Bio operates in the competitive biologics and antibodies space, with a focus on making epigenomic profiling more accessible and efficient. The company has not disclosed funding rounds or valuation, indicating a relatively nascent stage of development. However, its innovative approach to methylation analysis positions it well within the growing epigenomics market, which is driven by increasing demand for precision medicine and biomarker discovery. With its proprietary technology and streamlined workflows, Ellis Bio has the potential to capture significant market share, though execution risks remain given its early stage and the presence of established players in the space.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement60% success
• Q4 2026Launch of SuperMethyl™ v2 with Enhanced Capabilities70% success
• Q1 2027Strategic Partnership with a Major Research Institution or CRO50% success